{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T04:36:25Z","timestamp":1791088585376,"version":"4.1.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2007,3]]},"DOI":"10.2515\/therapie:2007023","type":"journal-article","created":{"date-parts":[[2007,6,20]],"date-time":"2007-06-20T10:48:32Z","timestamp":1182336512000},"page":"99-103","source":"Crossref","is-referenced-by-count":5,"title":["D\u00e9pistage des patients d\u00e9ficitaires en dihydropyrimidine d\u00e9hydrog\u00e9nase avant traitement par fluoropyrimidines"],"prefix":"10.1016","volume":"62","author":[{"given":"Erick","family":"Gamelin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mich\u00e8le","family":"Boisdron-Celle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Morel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.2515\/therapie:2007023_bb0005","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","article-title":"Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer","volume":"18","author":"de Gramont","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.2515\/therapie:2007023_bb0010","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(00)02034-1","article-title":"Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial","volume":"355","author":"Douillard","year":"2000","journal-title":"Lancet"},{"key":"10.2515\/therapie:2007023_bb0015","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1056\/NEJM198507253130407","article-title":"Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity","volume":"313","author":"Tuchman","year":"1985","journal-title":"New Engl J Med"},{"key":"10.2515\/therapie:2007023_bb0020","first-page":"2672","article-title":"Dihydropyrimidine dehydrogenase: its role in 5-Fluorouracil clinical toxicity and tumor resistance","volume":"5","author":"Diasio","year":"1999","journal-title":"Clin Can. Res"},{"key":"10.2515\/therapie:2007023_bb0025","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1200\/JCO.1994.12.11.2248","article-title":"Population study of dihydropyrimidine dehydrogenase in cancer patients","volume":"12","author":"EtienneMC","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.2515\/therapie:2007023_bb0030","first-page":"5433","article-title":"Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in -fluorouracil chemotherapy","volume":"53","author":"Lu","year":"1993","journal-title":"Cancer Res"},{"key":"10.2515\/therapie:2007023_bb0035","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1172\/JCI113308","article-title":"Familial deficiency of dihydropyrimidine dehydrogenase (biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity)","volume":"81","author":"Diasio","year":"1988","journal-title":"J Clin Invest"},{"key":"10.2515\/therapie:2007023_bb0040","first-page":"2006","article-title":"Life-threatening toxicity in a dihydropyrimidine dehydrogenase deficient patient after treatment with topical 5-Fluorouracil","volume":"5","author":"Johnson","year":"1999","journal-title":"Clin Canc Res"},{"key":"10.2515\/therapie:2007023_bb0045","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/ijc.10599","article-title":"Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1G>A mutation","volume":"101","author":"Van Kuilenburg","year":"2002","journal-title":"Int. J Cancer"},{"key":"10.2515\/therapie:2007023_bb0050","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1258\/000456303321016150","article-title":"Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency","volume":"40","author":"Van Kuilenburg","year":"2003","journal-title":"Ann Clin Biochem"},{"key":"10.2515\/therapie:2007023_bb0055","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/00008571-199812000-00001","article-title":"Nomenclature for human DPYD alleles","volume":"8","author":"Mc","year":"1998","journal-title":"Pharmacogenetics"},{"key":"10.2515\/therapie:2007023_bb0060","first-page":"4705","article-title":"Clinical implication of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-Fluorouracil-associated toxicity: identification of new mutations in the DPD gene","volume":"6","author":"Van Kuilenburg","year":"2000","journal-title":"Clin Can Res"},{"key":"10.2515\/therapie:2007023_bb0065","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/ijc.10599","article-title":"Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1G>A mutation","volume":"101","author":"Van Kuilenburg","year":"2002","journal-title":"Int J Cancer"},{"key":"10.2515\/therapie:2007023_bb0070","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1158\/1535-7163.MCT-06-0327","article-title":"Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms (SNP) upon 5-fluorouracil tolerance in a prospective clinical study in a french caucasian population","volume":"5","author":"Morel","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"10.2515\/therapie:2007023_bb0075","series-title":"Biological biomedical applications of liquid chromatography, III","first-page":"285","article-title":"HPLC of urinary pyrimidines for the evaluation of primary and secondary abnormalities of pyrimidine metabolism","author":"Van Gennip","year":"1982"},{"key":"10.2515\/therapie:2007023_bb0080","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1080\/10826079708000481","article-title":"Simple chromatographic method for the analysis of pyrimidines and their dihydrogenated metabolites","volume":"20","author":"Gamelin","year":"1997","journal-title":"J Liq Chrom Rel Technol"},{"key":"10.2515\/therapie:2007023_bb0085","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1200\/JCO.1999.17.4.1105","article-title":"Correlation between uracil and dihydrouracil plasma ratio, and 5-fluorouracil pharmacokinetic parameters and tolerance in patients with advanced colorectal cancer. A potential interest for predicting 5-FU toxicity and for determining optimal 5-FU dosage","volume":"17","author":"Gamelin","year":"1999","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.2515\/therapie:2007023_bb0090","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jchromb.2005.05.044","article-title":"An accurate Dihydrouracil\/Uracil determination using improved High Performance Liquid Chromatography method for preventing fluoropyrimidines-related toxicity in clinical practice","volume":"823","author":"Remaud","year":"2005","journal-title":"J Chromatogr B"},{"key":"10.2515\/therapie:2007023_bb0095","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.clinbiochem.2006.07.012","article-title":"Identification of a novel mutation in the dihydropyrimidine dehydrogenase gene in a patient with lethal outcome after 5-fluorouracil administration and determination of its frequency in a population of 500 patients with colorectal carcinoma","volume":"40","author":"Morel","year":"2007","journal-title":"Clin Biochem"},{"key":"10.2515\/therapie:2007023_bb0100","unstructured":"Boisdron-Celle M, Remaud G, Traore S, et al. 5-Fluororuacil-related severe toxicity: A comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency. Cancer letters (in press)."}],"container-title":["Therapies"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716304620?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716304620?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T03:05:02Z","timestamp":1554260702000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595716304620"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,3]]}},"alternative-id":["S0040595716304620"],"URL":"https:\/\/doi.org\/10.2515\/therapie:2007023","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2007,3]]}}}